MegaPro Biomedical Co., Ltd
TWO: 6827.TWO0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Taipei Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Jassy Wang
- Employees
- 27
- Headquarters
- Zhubei, Taiwan
- IPO year
- 2021
- Market cap
- NT$979.7M
- Website
- https://www.megaprobio.com
Loading 6827…
Loading profile data…Frequently asked questions about 6827
What does MegaPro Biomedical Co., Ltd (6827.TWO) do?
MegaPro Biomedical Co., Ltd, a biotech company, focuses on the development of nano drugs. It also develops MPB-1523, an IOP injection that is in Phase II clinical trial for use in the treatment of hepatocellular carcinoma; and MPB-1514, an iron injection that is in Phase II clinical trial for use in the treatment of iron deficiency anemia, as we...
Where does 6827.TWO trade?
MegaPro Biomedical Co., Ltd (6827.TWO) trades on the Taipei Exchange.
What sector is 6827.TWO in?
MegaPro Biomedical Co., Ltd (6827.TWO) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of MegaPro Biomedical Co., Ltd?
Jassy Wang is the chief executive officer of MegaPro Biomedical Co., Ltd (6827.TWO).
Where is MegaPro Biomedical Co., Ltd headquartered?
MegaPro Biomedical Co., Ltd is headquartered in Taiwan.
Does 6827.TWO pay a dividend?
MegaPro Biomedical Co., Ltd (6827.TWO) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 6827.TWO go public?
MegaPro Biomedical Co., Ltd (6827.TWO) completed its initial public offering in 2021.